Bioaccell
Bioaccell Inc. is a company based in Kyoto, Japan, specializing in advanced regenerative cell therapy and immune cell cultivation for cancer treatment. They focus on safe and highly effective cell culture technologies, supporting medical institutions with the cultivation and processing of therapeutic immune cells. The company is committed to providing personalized, effective cancer immunotherapy, including activated autologous lymphocyte therapy, dendritic cell therapy, and other innovative treatments. They also engage in collaborative research with international institutions and aim to make immunotherapy accessible and affordable for all patients.
Industries
Nr. of Employees
small (1-50)
Products
Dendritic cell vaccine for induction of cellular immunity (including NKT activation)
A dendritic cell–based vaccine designed to present tumor-associated or glycolipid antigens to induce cytotoxic T lymphocyte responses and to specifically activate NKT cells as part of cellular immunotherapy strategies.
Dendritic cell vaccine for induction of cellular immunity (including NKT activation)
A dendritic cell–based vaccine designed to present tumor-associated or glycolipid antigens to induce cytotoxic T lymphocyte responses and to specifically activate NKT cells as part of cellular immunotherapy strategies.
Services
Contract manufacturing of autologous immune-cell therapies
Contract services for ex vivo isolation, selective activation and expansion, quality control and supply of patient-derived immune cells for clinical use at partner medical institutions.
Technology transfer and preclinical support for cell-culture and activation methods
Collaborative provision of culture protocols, activation methods and technical guidance to research institutions and translational teams to enable preclinical studies and trial enabling work.
Integrated in-house quality control testing for cell therapy products
Testing services integrated into the manufacturing workflow to assess contamination and safety of cultured cells, including endotoxin and mycoplasma assays to support product release.
Contract manufacturing of autologous immune-cell therapies
Contract services for ex vivo isolation, selective activation and expansion, quality control and supply of patient-derived immune cells for clinical use at partner medical institutions.
Technology transfer and preclinical support for cell-culture and activation methods
Collaborative provision of culture protocols, activation methods and technical guidance to research institutions and translational teams to enable preclinical studies and trial enabling work.
Integrated in-house quality control testing for cell therapy products
Testing services integrated into the manufacturing workflow to assess contamination and safety of cultured cells, including endotoxin and mycoplasma assays to support product release.
Expertise Areas
- Autologous cell therapy manufacturing and supply
- Selective lymphocyte subset activation and expansion (αβ T, NK, γδ T)
- Dendritic cell vaccine development including NKT-targeting approaches
- Cleanroom cell processing facility operations and environmental control
Key Technologies
- Large-scale cell culture and expansion
- Subset-selective activation methods (anti-CD3, NK-stimulating antibodies)
- Dendritic cell vaccine manufacturing and antigen presentation techniques
- NKT activation via CD1d–glycolipid presentation